Suppr超能文献

定义和应用具有本地相关性的腺瘤检出率基准。

Defining and Applying Locally Relevant Benchmarks for the Adenoma Detection Rate.

机构信息

Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

Research Facilitation, Alberta Health Services, Calgary, Alberta, Canada.

出版信息

Am J Gastroenterol. 2019 Aug;114(8):1315-1321. doi: 10.14309/ajg.0000000000000120.

Abstract

INTRODUCTION

The adenoma detection rate (ADR) is the best validated colonoscopy performance quality indicator. The ASGE/ACG Task Force on Colonoscopy Quality set an ADR benchmark of ≥25% in a mixed male/female population. We propose a novel means for defining locally relevant ADR benchmarks using data from the population of interest and for applying ADR benchmarks using 95% confidence intervals (CIs) of an endoscopist's ADR. We further propose that ADR benchmarks should be raised to reflect what can be achieved by high-performing endoscopists.

METHODS

We used endoscopists' performance in a baseline year to develop and apply benchmarks in an assessment year. We defined assessment year benchmarks (Minimally Acceptable, Standard of Care, and Aspirational) based on the average ADR of performance groups defined by baseline year ADR quartiles. We demonstrated the use of these benchmarks in endoscopists performing screening colonoscopies by determining if the upper bound of the 95% CI of the endoscopist's ADR included the ADR benchmark.

RESULTS

The study included 8,492 colonoscopies (mean ADR 29%) in 2014 and 5,193 colonoscopies (mean ADR 32%) in 2015, completed at a regional screening center in Calgary, Canada. The Minimally Acceptable, Standard of Care, and Aspirational benchmarks for 2015 were 25%, 30%, and 39%, respectively. The 95% CI of the ADR of 1 (3%), 3 (10%), and 12 (39%) endoscopists did not include the benchmark.

DISCUSSION

We have proposed methods for defining and applying benchmarks for ADR in average-risk patients that go beyond the "minimally acceptable" threshold currently recommended.

摘要

简介

腺瘤检出率(ADR)是经过充分验证的结肠镜检查性能质量指标。美国胃肠内镜学会/美国胃肠病学会结肠内镜质量工作组设定了一个 ADR 基准,即混合性别人群中 ADR 不低于 25%。我们提出了一种新方法,使用感兴趣人群的数据来定义本地相关的 ADR 基准,并使用内镜医师 ADR 的 95%置信区间(CI)来应用 ADR 基准。我们进一步提出,应提高 ADR 基准,以反映高绩效内镜医师所能达到的水平。

方法

我们使用内镜医师在基线年内的表现来制定和评估年内的基准。我们根据基线年内 ADR 四分位区间定义的绩效组的平均 ADR,定义了评估年内的基准(最低可接受、标准护理和理想)。我们通过确定内镜医师 ADR 的 95%CI 的上限是否包含 ADR 基准,来演示这些基准在进行筛查性结肠镜检查的内镜医师中的应用。

结果

这项研究纳入了 2014 年进行的 8492 例(平均 ADR 为 29%)和 2015 年进行的 5193 例(平均 ADR 为 32%)结肠镜检查,这些检查均在加拿大卡尔加里的一个区域性筛查中心完成。2015 年的最低可接受、标准护理和理想 ADR 基准分别为 25%、30%和 39%。1(3%)、3(10%)和 12(39%)名内镜医师的 ADR 95%CI 不包括基准。

讨论

我们提出了一种方法,用于定义和应用平均风险患者的 ADR 基准,该方法超越了目前推荐的“最低可接受”阈值。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验